246results about How to "Efficient infection" patented technology

The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

A composition including a purified antibody conjugated with at least one antibiotic, the antibody having an antigen-binding portion that binds at least one antigen derived from Staphylococcus or Streptococcus.

An attenuated herpes virus capable of efficiently infecting a dendritic cell without preventing antigen processing occurring within the infected cell. The attenuated herpes virus and dentrictic cells infected with the virus are useful in immunotherapeutic methods of treating disease.

The present invention relates to retroviral vectors which will infect and confer efficient gene transfer to non-dividing cells including the cells of the central nervous system. The vector system of the present invention is useful as a gene transfer vehicle for gene therapy, i.e. of the central nervous system.

The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases and diseases of the soft tissues surrounding bones.

The invention relates to the field of genetic engineering, in particular to preparation of an infectious clone vector of a Pepper mild mottle virus (PMMoV) of RNA (ribonucleic acid) plant viruses and tobacco mosaic viruses, pathogenesis analysis on an infectiously cloned agrobacterium tumefaciens strain with the pepper mild mottle virus and exogenous proteins infectiously cloned and expressed by the aid of the PMMoV. The preparation, the pathogenesis analysis and exogenous proteins have the advantages that genomes of Shanghai bay isolate of the pepper mild mottle virus are constructed onto efficient plant expression vectors pCB301-CH by the aid of a genetic recombination process, the recombinant vectors are transferred into the agrobacterium tumefaciens strain by means of electroporation, and accordingly the virus vector with infection ability can be obtained; the plant expression vectors can be constructed by means of infectious cloning, and the exogenous proteins can be efficiently and stably expressed in host plants; mature systems can be provided for studying structures and functions of the virus genomes and studying interaction between the virus and hosts.

Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of the infective organism. Methods of treating a cefepime resistant bacterial infection in a patient are also provided.

Novel methods for treating and preventing arthritis, such as rheumatoid arthritis, are disclosed which employ lentiviral gene delivery vectors, including HIV-based lentiviral vectors, to deliver a therapeutic gene to a subject. Lentiviral-based vectors treat arthritis by promoting high-level expression of the transferred therapeutic gene in the target tissue of the subject.

The present invention relates to a novel orally administrable formulation of nitrofurantoin comprising a first component being a controlled release form, which comprises nitrofurantoin monohydrate, sodium alginate, alginic acid and hypromellose, and a second component being an immediate release form, which comprises macrocrystalline nitrofurantoin. A method for preparing said formulation and a method for treating a bacterial infection using said formulation are also described.

The present invention pertains to compositions for the treatment of HIV-related opportunistic infections and complications. More specifically, the present invention is directed to a composition comprising Zanthoxylum gillettii and Anogeissus leiocarpus, in combination with citrus juice, or biomass extracts isolated therefrom, and methods of using and manufacturing the same.

The present invention provides a computer virus infection information providing system for providing infection information such as the time of infection to the users and thereby permitting the users to understand the time of infection easily. Anti-virus software is installed in a central apparatus. The central apparatus further stores the communication history of the information transmitted by terminal apparatuses. When the installed anti-virus software detects a computer virus in the transmitted information, the time of infection is specified based on the stored communication history. The infection information including the specified time of infection is transmitted to a terminal apparatus. The terminal apparatus displays the transmitted infection information including the time of infection.

The present invention provides MSCRAMM® proteins from S. aureus which are putative highly-expressed antigens from methicillin-resistant S. aureus, including communit-associated MRSA (CA-MRSA), and these antigens can thus be utilized in methods of generating antibodies capable of binding these antigens which can be useful in methods of treating or preventing infection from MRSA. The present invention is directed to these proteins, antibodies capable of binding these proteins, methods of generating said antibodies, nucleic acids coding for said proteins, and pharmaceutical compositions or vaccines which include the proteins or antibodies of the present invention in combination with a pharmaceutically acceptable vehicle, carrier or excipient.

To provide peptides having high affinity for hemagglutinin and peptides having high inhibitory activity against influenza virus infection, as well as pharmaceutical compositions containing the peptides, the polypeptides having any one of SEQ ID NOs: 2 to 7, 9 to 10, and 12 to 18 are obtained by introducing mutation into a peptide having the sequence of ARLSPTMVHPNGAQP (peptide A-1: SEQ ID NO: 1) and screening for peptides having higher affinity for hemagglutinin. Further, the inhibitory activity of the peptide of SEQ ID NO: 3 against influenza virus infection can be enhanced by truncating SEQ ID NO: 3 in its C-terminus region with leaving ARLPR or ARLP. In addition, an influenza virus-infection inhibitor and an influenza preventive/therapeutic agent can be prepared by formulating these influenza virus receptor-binding peptides.

This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.

The invention discloses applications of CIZI gene and relevant medicines, discloses applications of CIZI gene in preparation or screening of oncological therapeutic medicines of liver cancer, lung cancer, breast carcinoma or glioma, further constructs separated nucleic acid molecules, CIZI gene interference nucleic acid construction bodies and CIZI gene interference lentivirus which can decrease expression of CIZI gene in tumor cells and discloses applications thereof. The nucleic acid molecules, nucleic acid construction bodies or CIZI gene interference lentivirus can inhibit the expression of the CIZI gene specifically. Especially, lentivirus can infect target cells efficiently, the expression of the CIZI gene in the target cells is inhibited efficiently, furthermore the growth of the tumor cells is inhibited, the apoptosis of the tumor cells is promoted, and the applications of CIZI gene and the relevant medicines are significant in oncotherapy.

The invention provides an adeno-associated virus (AAV) containing variant capsid protein and application of the AAV. The variant AAV-ie is constructed by inserting an amino acid sequence DGTLAVPFK between N589 and R590 of wild type AAV-DJ capsid protein VPI. The variant AAV-ie can efficiently infect hair cells and supporting cells, is greatly improved as compared with AAV-ie parents and provides better technical support for scientific research.

The present invention provides for a vector and a gene expression system for producing a soluble pentameric protein complex comprising the HCMV glycoproteins UL128, UL130, UL131, gH and gL or sequence variants thereof, as well as vaccine compositions comprising the same. The present invention further provides for a vaccine composition for use in prophylactically or therapeutically vaccinating against HCMV infections. Also disclosed are methods of producing the inventive vaccine. Furthermore, the present invention pertains to methods of vaccination of humans with the inventive vaccine composition.

The invention relates to a preparation method of a silver ion antibacterial medical dressing, and the preparation method comprises the following steps: dyeing, attaching a silver ion antibacterial agent, baking, mixing with viscose, weaving, slitting peritoneum, and preparing patch. Compared with similar products, the product has stronger infection resistance, can be used for remarkably accelerating wound healing, shortening the course of treatment and reducing the formation of scars. Clinical application proves that the silver ion antibacterial medical dressing is applicable to treatment of I-type, II-type and III-type cuts after an operation, has the advantages of safety, reliability, efficiency, no allergy occurrence and the like, and is suitable for clinical popularization and application.

In accordance with the present invention, there is to provide a dietary supplement that provides a mammal with the essential carbohydrates needed to maintain proper health and functionality, to fend off illness, to provide an alternative treatment for exercise induced asthma and asthma related illnesses, to lessen the aging process of cells and to provide pets with another level of medications equal to that for humans.

The invention discloses separation and application of a high-lysis-rate salmonella phage RDP-SA-17118. The host of the salmonella phage RDP-SA-17118 is salmonella S6, and the phage can form a plaque with a diameter of 2mm-4mm on double plates. Through observation by an electron microscope, the phage has a polyhedral stereosymmetric head which wraps nucleic acid and has a diameter of 70nm; the phage has a tail with a length of 120nm and has a tail sheath; a neck is connected with the head and the tail; and the phage belongs to myoviridae of caudovirales. The phage has a high titer of 10<12> pfu/mL and has good tolerance to temperature and pH value, and the titer still keeps 10<12>pfu/mL or above after continuous passage for 29 times. The phage has a good lysis effect on a host after being diluted by 10<6> times, and after the phage is fed, existence of the phage can be detected in heart, liver, lung, kidney, thymus and serum. Through animal experiments, the phage has a good effect in treating chicken salmonella diseases.

The invention belongs to the technical field of food production, and particularly relates to a winter health-preservation tea bag and a preparation method thereof. The winter health-preservation tea bag is prepared from 2-5 parts of red jujubes, 1-3 parts of Chinese wolfberry fruits, 0.5-3 parts of ginseng, 0.5-2 parts of rhizoma polygonati, 1-4 parts of black tea and 0.1-0.5 part of oligopeptide powder. A formula of the winter health-preservation tea bag is matched according to a four-season health-preservation principle and a winter health-preservation principle of traditional Chinese medicines, high-quality raw materials are preferably selected, the ginseng and the rhizoma polygonati are used for nourishing qi and the spleen, the red jujubes are used for nourishing blood, the Chinese wolfberry fruits are used for enriching yin and nourishing the kidney, the black tea is used for warming and tonifying the stomach, and besides, the oligopeptide powder is added, so that the immunity of organisms is enhanced, when people drinks the winter health-preservation tea bag for a long time, the effects of benefitting qi, eliminating fatigue, promoting production of body fluid, soothing nerves, and nourishing the kidney can be achieved, and the health-preservation health-care purposes are achieved.

The invention discloses applications a correlated medicament of a human STIM1 gene. The invention discloses applications of the human STIM1 gene in tumor treatment, tumor diagnosis and medicament preparation. The invention also further constructs a human STIM1 gene small-interfering ribonucleic acid (siRNA), a human STIM1 gene interfering nucleic acid construct, a human STIM1 gene interfering slow virus and applications thereof. The siRNA or nucleic acid construct and slow virus comprising the siRNA sequence can specifically inhibit the expression of the human STIM1 gene, particularly, the slow virus can infect a target cell efficiently so as to effectively inhibit the expression of STIM1 gene in the target cell, thus further inhibiting the growth of tumor cells and promoting apoptosis of the tumor cells. Therefore, the human STIM1 gene has important significance in tumor treatment.

The invention discloses a zika virus vaccine based on a chimpanzee adenovirus vector and a preparation method thereof, which belong to the field of a biotechnology and virology. A chimpanzee adenovirus AdC 7 is constructed as a replication defective type recombinant expression vector with favorable immunogenicity and hereditary stability, and the novel zika virus vaccine is prepared based on the vector. After mice are immunized through the vaccine, a neutralizing antibody aiming at a zika virus can be effectively induced, so that the mice are protected against being infected, and meanwhile, tissues and organs of the mice can be protected against being damaged.

A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.

The present invention relates to compositions and methods for making and using Omi-related and IAP-cleaving nucleotide sequences, mutant nucleotide sequences, and polypeptide sequences expressed therefrom, including both biologically active and inactive molecules. The present invention relates to cleaving IAP using an Omi polypeptide.